Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
- Q2 2023 revenue was
$8.7 million, which represents a 30% increase over Q2 2022
- Installed base of Saphyr® systems totaled 281 as of
June 30, 2023, which represents a 43% increase over Q2 2022
- Sold 7,062 nanochannel array flowcells as of
June 30, 2023, which represents a 108% increase over the number of flowcells sold in Q2 2022
- Conference call today,
August 9th, 2023, at 4:30 PM ET
Q2 2023 Highlights
- Installed base of Saphyr® systems totaled 281 at the end of the second quarter 2023, which was an increase of 22 systems over the first quarter of 2023 and represents a 43% increase over the 196 installed systems reported at the end of the second quarter of 2022.
- 7,062 nanochannel array flowcells sold during the second quarter, which represents a 35% increase over the 5,226 flowcells sold during the first quarter of 2023 and represents an increase of 108% over the 3,394 flowcells sold during the second quarter of 2022.
- Announced the commercial release of new kits for the Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue. These products offer potential improvements in quality and yield of nucleic acid extracted from complex biological samples including those with low cell counts or otherwise challenging sample types, such as FFPE tumor samples.
- Announced the Stratys™ system for high throughput optical genome mapping (OGM), which will enable a four-fold increase in raw data generation rate compared to the Saphyr® instrument. The Stratys instrument is compatible with the Company’s latest G2 chemistry and is designed for maximum lab flexibility by enabling up to 12 single access chips, accessible as they complete runs, without the need to batch multiple samples on a consumable.
- Announced VIA™ software, which replaces NxClinical™ software with a simple and integrated workflow for visualization, interpretation and reporting for hematologic malignancies across OGM, microarray and next-generation sequencing (NGS) data types for enhanced contextualization across multiple variant types and accelerated time to results at a reduced cost. A workflow focused on genetic disease is expected later in 2023.
- Announced the 2023 winners of the Bionano Innovator Research Grant program, which was established to fuel novel research using the Company’s OGM products to detect relevant structural variants (SVs). There were over 190 grant applications submitted from 46 countries and 15 winners were selected, including researchers from grand prize winner
Stanford University, and runner up prize winners The Hospital for Sick Children and Duke University. All three winners will receive use of a Saphyr system and OGM reagents to conduct their project.
- Bionano participated at key cytogenetic conferences, including the European Hematology Association (EHA) 2023 Congress, the European Human Genetics (ESHG) 2023 Conference, the European Association for Cancer Research (EACR) 2023 Congress and the International Society for Stem Cell Research (ISSCR) Annual Meeting 2023. OGM was featured in 37 scientific posters and presentations covering a wide range of research applications across key areas including constitutional genetic disorders, rare undiagnosed genetic disease (RUGD), solid tumor analysis, hematological malignancies, stem cell research and regenerative medicine.
- Key studies that were published during Q2 outline support for OGM’s utility for cancer and genetic disease research:
- Three peer-reviewed publications collectively illustrate the building support in Europe for OGM as a powerful alternative to traditional methods of cytogenetic analysis for hematological malignancies. Taken together, the publications, a review paper and two independent studies, illustrate that OGM is not only comparable to traditional methods of cytogenetic analysis for hematological malignancies but is potentially more sensitive in the detection of relevant aberrations that are not detected by traditional methods but that could have an impact on clinical research, potentially leading to improved patient management, including therapy selection and overall risk assessment.
- A peer-reviewed study from Augusta University assessed the utility of a combined OGM and 523-gene next-generation sequencing (NGS) panel workflow for the standard evaluation of samples from 30 myeloid cancer subjects and compared it to the common approach of KT and FISH combined with a 54-gene NGS panel. The authors found that the combined workflow of OGM plus the 523-gene NGS panel performed significantly better than KT and FISH, identifying previously undetected pathogenic SVs and resulting in revisions to risk classifications and disease stratifications.
- Researchers at Radboud University Medical Center published a study showing the use of OGM to identify gene disruptive SVs that might contribute to inherited retinal diseases (IRDs). The authors sought to determine whether OGM could improve SV detection in genetically unexplained IRD cases. Their results identified several pathogenic SVs that had been overlooked in their initial genome analyses by NGS, illustrating the potential impact of combining NGS and OGM for more comprehensive variant analysis.
“We are pleased with our Q2 2023 results, which include record revenues and consumable sales for any quarter in Bionano’s history,” commented
Q2 2023 Financial Highlights
- Total revenue for the second quarter of 2023 was
$8.7 million, an increase of 30% compared to the second quarter of 2022.
- GAAP gross margin for the second quarter of 2023 was 27%, compared to 22% from the second quarter of 2022. Second quarter 2023 non-GAAP¹ gross margin was 29%, compared to 22% from the second quarter of 2022. Second quarter 2023 non-GAAP gross margin excludes
$0.2 millionin stock-based compensation.
- Second quarter 2023 GAAP operating expense was
$41.5 million, compared to $33.6 millionin the second quarter of 2022. Second quarter 2023 non-GAAP operating expense was $34.6 million, compared to $26.3 millionin the second quarter of 2022. Second quarter 2023 non-GAAP operating expenses exclude $3.7 millionin stock-based compensation, $1.8 millionin amortization of intangibles, and a $1.4 millionincrease in the estimated fair value of the contingent consideration liabilities primarily related to the acquisition of Purigen Biosystems.
- Cash, cash equivalents, and available-for-sale securities were
$77.1 millionas of June 30, 2023, compared to cash, cash equivalents and available-for-sale securities of $95.8 millionas of March 31, 2023.
|Live Call:||Registration – Click Here
Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
Bionano is a provider of genomic analysis solutions that can help reveal answers to challenging genetic questions. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM). Our OGM solutions allow scientists and clinical researchers the ability to see and discover structural variations in a way unmatched by traditional cytogenetic techniques. Our products additionally include an industry-leading, platform-agnostic software solution, which integrates OGM, next-generation sequencing and microarray data in one consolidated view, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Our Lineagen, Inc., d/b/a Bionano Laboratories, business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. To learn more, visit bionano.com and connect with us on Twitter, LinkedIn, Instagram, and YouTube.
Unless specifically noted otherwise, Bionano products are provided for Research Use Only. Not for use in diagnostic procedures.
Non-GAAP Financial Measures
To supplement Bionano’s financial results reported in accordance with
Bionano believes that non-GAAP gross margin and non-GAAP operating expense are useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing operating performance and identifying operating trends in its business. Bionano uses non-GAAP gross margin and non-GAAP operating expense internally to facilitate period-to-period comparisons and analysis of its operating performance in order to understand, manage and evaluate its business and to make operating decisions. Accordingly, Bionano believes these measures allow for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Bionano in this press release and the accompanying reconciliation table have limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
For a reconciliation of non-GAAP gross margin and non-GAAP operating expense to gross margin and operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this release.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “estimate,” “expect,” “may,” “plan,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential for the new Ionic® Purification System to improve the quality and yield of samples, the commercial rollout of the Stratys™ system for high throughput OGM, the timing of a workflow focused on genetic diseases using VIA™ software, our expectations regarding product uptake, revenue growth, market development and increased OGM adoption, including through publications highlighting the utility and applications of OGM; our growth prospects and future financial and operating results, including our compound annual growth in revenues; the growth of our installed Saphyr system base; the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our stated goals, including to drive value and penetrate into our target markets; our recent and upcoming product releases helping us penetrate new markets and achieve our business goals; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; our ability to drive adoption of OGM and our technology solutions; the execution of our stated strategy, and previously announced cost savings actions reflecting in operating expense for the second half of 2023. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal period; the impact of adverse geopolitical and macroeconomic events, such as recent and potential future bank failures, potential resurgences of COVID-19 and the ongoing conflict between
+1 (858) 888-7610
+1 (858) 888-7625
|Condensed Consolidated Balance Sheet (Unaudited)|
|Cash and cash equivalents||$||14,856,000||$||5,091,000|
|Accounts receivable, net||7,613,000||7,022,000|
|Prepaid expenses and other current assets||5,447,000||7,329,000|
|Total current assets||122,575,000||157,298,000|
|Property and equipment, net||20,263,000||18,029,000|
|Operating lease right-of-use asset||6,697,000||7,222,000|
|Financing lease right-of-use asset||3,606,000||3,707,000|
|Intangible assets, net||37,559,000||41,143,000|
|Other long-term assets||3,000,000||2,414,000|
|Liabilities and stockholders’ equity|
|Operating lease liability||2,014,000||2,260,000|
|Finance lease liability||279,000||285,000|
|Total current liabilities||33,499,000||35,884,000|
|Operating lease liability, net of current portion||4,766,000||5,504,000|
|Finance lease liability, net of current portion||3,604,000||3,619,000|
|Contingent consideration, net of current portion||14,570,000||12,970,000|
|Long-term contract liabilities||186,000||127,000|
|Additional paid-in capital||639,814,000||599,234,000|
|Accumulated other comprehensive loss||(310,000||)||(1,124,000||)|
|Total stockholders’ equity||214,756,000||249,398,000|
|Total liabilities and stockholders’ equity||$||271,381,000||$||307,502,000|
|Condensed Consolidated Statement of Operations (Unaudited)|
|Three Months Ended
||Six Months Ended
|Service and other revenue||2,053,000||1,875,000||4,021,000||3,365,000|
|Cost of revenue:|
|Cost of product revenue||4,752,000||3,973,000||8,610,000||7,549,000|
|Cost of service and other revenue||1,602,000||1,226,000||3,090,000||2,485,000|
|Total cost of revenue||6,354,000||5,199,000||11,700,000||10,034,000|
|Research and development||14,610,000||11,767,000||28,547,000||22,296,000|
|Selling, general and administrative||26,936,000||21,783,000||52,913,000||42,060,000|
|Total operating expenses||41,546,000||33,550,000||81,460,000||64,356,000|
|Loss from operations||(39,238,000||)||(32,079,000||)||(77,083,000||)||(62,024,000||)|
|Other income (expenses):|
|Other income (expense)||(256,000||)||(156,000||)||(139,000||)||(188,000||)|
|Total other income (expense)||359,000||(38,000||)||1,104,000||(38,000||)|
|Loss before income taxes||(38,879,000||)||(32,117,000||)||(75,979,000||)||(62,062,000||)|
|Provision for income taxes||(33,000||)||(41,000||)||(59,000||)||(50,000||)|
|Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (Unaudited)|
|Three Months Ended
||Six Months Ended
|GAAP gross margin:|
|GAAP cost of revenue||6,354,000||5,199,000||11,700,000||10,034,000|
|GAAP gross profit||2,308,000||1,471,000||4,377,000||2,332,000|
|GAAP gross margin %||27||%||22||%||27||%||19||%|
|Adjusted non-GAAP gross margin:|
|GAAP cost of revenue||6,354,000||5,199,000||11,700,000||10,034,000|
|Stock-based compensation expense||(198,000||)||—||(344,000||)||—|
|Adjusted non-GAAP cost of revenue||6,156,000||5,199,000||11,356,000||10,034,000|
|Adjusted non-GAAP gross profit||2,506,000||1,471,000||4,721,000||2,332,000|
|Adjusted non-GAAP gross margin %||29||%||22||%||29||%||19||%|
|GAAP operating expense|
|GAAP selling, general and administrative expense||$||26,936,000||$||21,783,000||$||52,913,000||$||42,060,000|
|Stock-based compensation expense||(2,433,000||)||(2,309,000||)||(4,812,000||)||(4,084,000||)|
|Intangible asset amortization||(1,793,000||)||(1,419,000||)||(3,585,000||)||(2,838,000||)|
|Change in fair value of contingent consideration||(1,429,000||)||(79,000||)||(2,218,000||)||(158,000||)|
|Adjusted non-GAAP selling, general and administrative expense||21,281,000||17,976,000||42,298,000||34,980,000|
|GAAP research and development expense||$||14,610,000||$||11,767,000||$||28,547,000||$||22,296,000|
|Stock-based compensation expense||(1,301,000||)||(3,468,000||)||(2,658,000||)||(6,795,000||)|
|Adjusted non-GAAP research and development expense||13,309,000||8,299,000||25,889,000||15,501,000|
|Total adjusted non-GAAP operating expense||$||34,590,000||$||26,275,000||$||68,187,000||$||50,481,000|
1Non-GAAP gross margin and operating expense are non-GAAP financial measures. For a description of these non-GAAP financial measures, please refer to “Non-GAAP Financial Measures”, and for a reconciliation of non-GAAP cost of revenue and operating expense to cost of revenue and operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this release.
Source: Bionano Genomics